Bullet, David y Wikman Jorgensen, Philip Erick y Galvan, Vicente Giner y Rubio Rivas, Manuel y by Miguel Campo, Borja y Lopez, Mariam Noureddine y Lopez Caleya, Juan Francisco y Strikes, Ricardo Gomez y Pesqueira Fontán, Paula Maria y Bailon, Manuel Mendez y Fernandez Garces, Sea y Fernandez Cruz, Ana y Garcia Garcia, Gema Maria y Rhyman, Nicholas y Corral Gudino, Luis y Rodríguez Mancheño, Aquiles Lozano y From the Girl, Maria Navarro y Torregrosa Garcia, Andrea y Alcala, Jose Nicholas y Diaz Jimenez, Paul y Royo Trallero, Leticia Esther y Comas Casanova, Pere y Nunez Cortes, Jesus Millan y Casas Rojo, Jose-Manuel
(2021)
Evolution of the Use of Corticosteroids for the Treatment of Hospitalised COVID-19 Patients in Spain between March and November 2020: SEMI-COVID National Registry.
Journal of Clinical Medicine, 10
(19).
p. 4610.
ISSN 2077-0383
Official URL: https://doi.org/10.3390/jcm10194610
Summary
Objectives: Since the results of the RECOVERY trial, WHO recommendations about the use of corticosteroids (CTs) in COVID-19 have changed. The aim of the study is to analyse the evolutive use of CTs in Spain during the pandemic to assess the potential influence of new recommendations. Material and methods: A retrospective, descriptive, and observational study was conducted on adults hospitalised due to COVID-19 in Spain who were included in the SEMI-COVID-19 Registry from March to November 2020. Results: CTs were used in 6053 (36.21%) of the included patients. The patients were older (mean (SD)) (69.6 (14.6) vs. 66.0 (16.8) years; p < 0.001), with hypertension (57.0% vs. 47.7%; p < 0.001), obesity (26.4% vs. 19.3%; p < 0.0001), and multimorbidity prevalence (20.6% vs. 16.1%; p < 0.001). These patients had higher values (mean (95% CI)) of C-reactive protein (CRP) (86 (32.7–160) vs. 49.3 (16–109) mg/dL; p < 0.001), ferritin (791 (393–1534) vs. 470 (236–996) µg/dL; p < 0.001), D dimer (750 (430–1400) vs. 617 (345–1180) µg/dL; p < 0.001), and lower Sp02/Fi02 (266 (91.1) vs. 301 (101); p < 0.001). Since June 2020, there was an increment in the use of CTs (March vs. September; p < 0.001). Overall, 20% did not receive steroids, and 40% received less than 200 mg accumulated prednisone equivalent dose (APED). Severe patients are treated with higher doses. The mortality benefit was observed in patients with oxygen saturation
Downloads in the last year
Repository Staff Only: Article Control Page
2023-04-24 11:15:37
#Evolution #Corticosteroids #Treatment #Hospitalised #COVID19 #Patients #Spain #March #November #SEMICOVID #National #Registry
